论文信息 - A Case of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy. - 字舞流文

A Case of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.

Kareem Sioufi | Sudeep Das | E. Say

[1] L. Pablo,et al. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS. , 2019, Retina.

[2] Manish R. Patel,et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. , 2017, Cancer discovery.

[3] L. Yannuzzi,et al. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. , 2017, Ophthalmology.

[4] K. Flaherty,et al. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. , 2016, JAMA ophthalmology.

[5] J. Keunen,et al. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. , 2015, Ophthalmology.

[6] A. Hauschild,et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.